Other

Pfizer sees Covid-19 drug sales topping $50 bn in 2022

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Vaccination

Pfizer asks FDA to allow COVID-19 vaccine for kids under 5

Pfizer on Tuesday asked the U.S. to authorize extra-low doses of its COVID-19 vaccine for children under 5, potentially opening the way for the very youngest Americans to start receiving shots as early as March.

Vaccination

Pfizer booster more than 50% protective against omicron

A booster dose of the Pfizer–BioNTech vaccine (BNT162b2) against SARS-CoV-2 after an initial two doses of either the CoronaVac inactivated virus vaccine or Pfizer–BioNTech mRNA vaccine is shown to provide protection against ...

Vaccination

US advisers debate Pfizer boosters for younger teens

An influential government advisory panel is considering COVID-19 boosters for younger teens, as the U.S. battles the omicron surge and schools struggle with how to restart classes amid the spike.

Diseases, Conditions, Syndromes

Serious adverse effects from COVID-19 vaccines reported rarely

(HealthDay)—Patient-reported data indicate certain factors, such as vaccine brand (mRNA-1273) and younger age, are associated with an increased risk for adverse effects following COVID-19 vaccination, but serious adverse ...

page 10 from 40